Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.46 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 3/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358515 | 0.83 | ESR1 (0.63) | ESR1ESR2ENPP1ENPP3PSMB1 | |
| SCHEMBL8473855 | 0.82 | ESR1 (0.55) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL8473947 | 0.81 | ESR1 (0.58) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL13945577 | 0.81 | ESR1 (0.55) | ESR1ESR2ENPP1ENPP3PSMB1 | |
| SCHEMBL5430797 | 0.80 | ESR1 (0.58) | ESR1ESR2ENPP1ENPP3PSMB1 | |
| SCHEMBL1360002 | 0.80 | ESR1 (0.56) | ESR1ESR2ENPP1ENPP3PSMB1 | |
| SCHEMBL1359174 | 0.80 | ESR1 (0.56) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL1358405 | 0.80 | ESR1 (0.56) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL1358022 | 0.80 | ESR1 (0.56) | ESR1ESR2ENPP1ENPP3PSMB1 | |
| SCHEMBL8472729 | 0.80 | ESR1 (0.58) | ESR1ESR2ENPP1ENPP3PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221163-A1 | Selective Estrogen Receptor Modulators | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221163-A1 | Selective Estrogen Receptor Modulators | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885ENPP1 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.